Add BrightSurf on Google Email

Lower costs associated with late-preterm steroid therapy, NIH-funded analysis finds

A recent analysis found that giving the steroid betamethasone to pregnant women at risk of late-preterm delivery results in lower hospital stays for infants. The study estimated costs for over 1,400 mother-infant pairs and found that the average cost for those who received the drug was $4,681, compared to $5,379 for those who did not.

BU conducts first experimental evaluation of pharmaceutical industry-led access program

A new study by Boston University School of Public Health evaluates the Novartis Access program in Kenya, demonstrating that robust, 'gold standard' methods can be used to assess major pharmaceutical companies' access programs. The study found that the program significantly increased availability of two medicines in health facilities bu...

SourceBoston University School of Medicine·JournalThe Lancet Global Health·DateMar 5, 2019

Follow-up phone calls by pharmacists help patients after hospital discharge

A new study published in the British Journal of Clinical Pharmacology finds that pharmacist-led follow-up calls can significantly reduce hospital readmission rates and improve patient outcomes. The intervention also had positive effects on healthcare costs, patient beliefs about medicines, and patient satisfaction.

SourceWiley·JournalBritish Journal of Clinical Pharmacology·DateJan 24, 2019

Price disclosure legislation unlikely to lower drug costs

A new study published in JAMA Internal Medicine suggests that price disclosure legislation may not be effective in lowering drug costs. The research found that consumers are less likely to ask about high-priced drugs if they see a clear price disclosure, but this effect is short-lived and can be undermined by coupon programs.

SourceClemson University·JournalJAMA Internal Medicine·DateJan 22, 2019

Daily medication more cost-effective than monthly injections for opioid use disorder

A daily dose of buprenorphine-naloxone is cost-effective compared to monthly injections of extended-release naltrexone, with similar effectiveness in quality of life and time abstaining from opioids. The researchers conclude that buprenorphine-naloxone should be preferred as the first-line treatment for opioid use disorder.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·DateDec 17, 2018

ID specialist input improves outcomes for outpatient parenteral antimicrobial therapy

The Infectious Diseases Society of America (IDSA) has released new guidelines for outpatient parenteral antimicrobial therapy (OPAT), emphasizing the importance of review by an infectious diseases specialist before starting treatment. Regular monitoring and blood tests are also recommended to ensure patient safety.

SourceInfectious Diseases Society of America·JournalClinical Infectious Diseases·DateNov 13, 2018

NSF awards two grants for polymer research

Researchers at Virginia Tech aim to create new ways to use renewably sourced plant and wood polymers to tackle long-standing challenges in medical drug solubility. The project focuses on designing biodegradable polymers that can help orally administered drugs reach the bloodstream effectively.

Interventions to delay and prevent type 2 diabetes are underused, researchers say

Lifestyle interventions, medication, and surgery can effectively delay or prevent type 2 diabetes in the majority of patients, but limited access to these treatments is a major issue. Evidence-based interventions show that weight loss through lifestyle changes or metabolic surgery can reduce the risk of diabetes by up to 78%.

SourceAmerican Osteopathic Association·JournalThe Journal of the American Osteopathic Association·DateOct 29, 2018

Restrictive abortion laws in Northern Ireland affect women's health, study shows

Research from the LBJ School of Public Affairs found that Northern Ireland's strict abortion laws have negative consequences for women's physical and mental well-being. Women often face barriers to accessing care, including fear of prosecution, lack of clarity on healthcare provider duties, and challenges in arranging travel or childcare.

SourceUniversity of Texas at Austin·JournalBMJ Sexual & Reproductive Health·DateOct 19, 2018

Open insulin, 'DIY bio' and the future of pharma

The DIY bio movement is disrupting the pharmaceutical industry with open-source protocols for manufacturing off-patent insulin, increasing competition and potentially making life-saving medicine more affordable. The Open Insulin Project, a case study, aims to develop and release an open-source protocol for manufacturing insulin.

SourceColorado State University·JournalTrends in Biotechnology·DateSep 13, 2018

Insuring patient access and affordability for treatments for rare and ultra-rare diseases

The American College of Medical Genetics and Genomics emphasizes the need for affordable treatment options for rare and ultra-rare diseases. Key recommendations include preventing abuses of the Orphan Drug Act and aligning drug packaging with dosing recommendations to reduce waste. The organization urges policymakers to develop simple,...

SourceAmerican College of Medical Genetics and Genomics·JournalGenetics in Medicine·DateSep 7, 2018

Potential solutions to drug shortages and the lack of competition in generic medicines

The authors propose increasing incentives and modifying regulations to improve competition, redirecting overinvestment in new drug development to the generic market, and pivoting from short-term survival mode to long-term organized responses. These solutions aim to enhance competition, provide patients with reliable access to vital dru...

SourceBrigham and Women's Hospital·JournalJournal of General Internal Medicine·DateAug 9, 2018